NDA filed in Japan for satralizumab as NMOSD therapy

8 November 2019
chugai-large

A new drug application has been filed with the Japanese Ministry of Health, Labor and Welfare (MHLW) for satralizumab (development code: SA237), an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

Satralizumab received orphan drug designation from the MHLW on September 12, 2019, and the applications will be reviewed under priority review, said the drug’s development Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss pharma giant Roche (ROG: SIX).

“With our proprietary recycling antibody technology, satralizumab is designed to inhibit the signal transduction of IL-6, an inflammatory cytokine that is related to the pathology of NMOSD, by subcutaneous administration once every 4 weeks. In clinical study with the overall population, NMOSD patients including both aquaporin-4 antibodies [AQP4-IgG] seropositive and seronegative patients, clinically significant therapeutic effects were shown either in monotherapy or add-on therapy to baseline treatment,” said Dr Yasushi Ito, Chugai’s executive vice president, co-head of Project & Lifecycle Management Unit, adding: “We believe that the efficacy and safety demonstrated by satralizumab will lead to the provision of a new treatment option to patients. We will work for the approval of satralizumab to provide patients with this new treatment as soon as possible.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology